BR112021017702A2 - Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe - Google Patents
Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bheInfo
- Publication number
- BR112021017702A2 BR112021017702A2 BR112021017702A BR112021017702A BR112021017702A2 BR 112021017702 A2 BR112021017702 A2 BR 112021017702A2 BR 112021017702 A BR112021017702 A BR 112021017702A BR 112021017702 A BR112021017702 A BR 112021017702A BR 112021017702 A2 BR112021017702 A2 BR 112021017702A2
- Authority
- BR
- Brazil
- Prior art keywords
- function
- blood
- sequence
- brain barrier
- bhe
- Prior art date
Links
- 230000006866 deterioration Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000005962 receptors Human genes 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 4
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000030767 Autoimmune encephalitis Diseases 0.000 abstract 1
- 208000009137 Behcet syndrome Diseases 0.000 abstract 1
- 208000006547 Central Nervous System Lupus Vasculitis Diseases 0.000 abstract 1
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 abstract 1
- 206010063663 Neuropsychiatric lupus Diseases 0.000 abstract 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 abstract 1
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 208000011235 central nervous system lupus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 208000008795 neuromyelitis optica Diseases 0.000 abstract 1
- 208000000288 neurosarcoidosis Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000001578 tight junction Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
inibidor contendo anticorpo antireceptor de il-6 para inibição de deterioração da função bhe. a presente invenção refere-se a repressores de redução da função da barreira hematoencefálica (bhe), supressores da interrupção das junções de oclusões da barreira hematoencefálica, repressores de infiltração de leucócitos no cns, repressores de permeação de iggs de sangue de paciente no cns, e agentes terapêuticos para distúrbio de espectro de neuromielite ótica, doença neuro-behcet, neurosarcoidose, lúpus do sistema nervoso central (lúpus neuropsiquiátrico), encefalite autoimune, ou doença vogt-koyanagi-harada que reprimem redução da função da barreira hematoencefálica e/ou restauram reduzida função da barreira hematoencefálica, os quais contêm um anticorpo contendo uma região variável de cadeia pesada contendo cdr1 tendo a seq id nº: 1, cdr2 tendo a sequência de seq id nº: 2, e cdr3 tendo a sequência de seq id nº: 3, e uma região variável de cadeia leve contendo cdr1 tendo a sequência de seq id nº: 4, cdr2 tendo a sequência de seq id nº: 5, e cdr3 tendo a sequência de seq id nº: 6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019068693 | 2019-03-29 | ||
| PCT/JP2020/005965 WO2020202839A1 (ja) | 2019-03-29 | 2020-02-17 | 抗ｉｌ－６受容体抗体を含有するｂｂｂ機能低下の抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017702A2 true BR112021017702A2 (pt) | 2021-11-16 |
Family
ID=72667972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017702A BR112021017702A2 (pt) | 2019-03-29 | 2020-02-17 | Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220220210A1 (pt) |
| EP (1) | EP3949989A4 (pt) |
| JP (1) | JPWO2020202839A1 (pt) |
| KR (1) | KR20210144795A (pt) |
| CN (1) | CN113660951A (pt) |
| AU (1) | AU2020255449A1 (pt) |
| BR (1) | BR112021017702A2 (pt) |
| CA (1) | CA3133610A1 (pt) |
| IL (1) | IL286716A (pt) |
| MX (1) | MX2021011464A (pt) |
| TW (1) | TW202102540A (pt) |
| WO (1) | WO2020202839A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
| CA3233924A1 (en) * | 2021-10-08 | 2023-04-13 | Kengo ARAI | Method for preparing prefilled syringe formulation |
| WO2023140269A1 (en) * | 2022-01-19 | 2023-07-27 | Chugai Seiyaku Kabushiki Kaisha | Treatment of autoimmune encephalitis with satralizumab |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| JP3370324B2 (ja) | 1991-04-25 | 2003-01-27 | 中外製薬株式会社 | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| BRPI0915928B8 (pt) * | 2008-07-17 | 2021-05-25 | Novartis Ag | anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| AU2010225951B2 (en) | 2009-03-19 | 2014-03-13 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical formulation containing improved antibody molecules |
| RU2524152C2 (ru) | 2009-03-19 | 2014-07-27 | Чугаи Сейяку Кабусики Кайся | Средство для лечения ревматоидного артрита |
| TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
| DK2766093T3 (en) * | 2011-10-11 | 2018-06-06 | Vaccinex Inc | USE OF SEMAPHORIN-4D BINDING MOLECULES FOR MODULATING THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER |
| EP4056993A1 (en) * | 2014-08-20 | 2022-09-14 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
| US11447752B2 (en) | 2016-04-15 | 2022-09-20 | Yamaguchi University | In vitro model for blood-brain barrier and method for producing in vitro model for blood-brain barrier |
-
2020
- 2020-02-17 AU AU2020255449A patent/AU2020255449A1/en active Pending
- 2020-02-17 CN CN202080025917.0A patent/CN113660951A/zh active Pending
- 2020-02-17 JP JP2021511193A patent/JPWO2020202839A1/ja active Pending
- 2020-02-17 US US17/437,448 patent/US20220220210A1/en active Pending
- 2020-02-17 WO PCT/JP2020/005965 patent/WO2020202839A1/ja unknown
- 2020-02-17 CA CA3133610A patent/CA3133610A1/en active Pending
- 2020-02-17 MX MX2021011464A patent/MX2021011464A/es unknown
- 2020-02-17 BR BR112021017702A patent/BR112021017702A2/pt unknown
- 2020-02-17 TW TW109105023A patent/TW202102540A/zh unknown
- 2020-02-17 KR KR1020217034263A patent/KR20210144795A/ko unknown
- 2020-02-17 EP EP20783563.8A patent/EP3949989A4/en active Pending
-
2021
- 2021-09-26 IL IL286716A patent/IL286716A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3949989A4 (en) | 2022-12-14 |
| MX2021011464A (es) | 2021-10-22 |
| CN113660951A (zh) | 2021-11-16 |
| KR20210144795A (ko) | 2021-11-30 |
| WO2020202839A1 (ja) | 2020-10-08 |
| AU2020255449A1 (en) | 2021-10-07 |
| TW202102540A (zh) | 2021-01-16 |
| JPWO2020202839A1 (pt) | 2020-10-08 |
| IL286716A (en) | 2021-12-01 |
| CA3133610A1 (en) | 2020-10-08 |
| EP3949989A1 (en) | 2022-02-09 |
| US20220220210A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017702A2 (pt) | Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe | |
| Haanen et al. | Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy | |
| Sznol et al. | Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| JP2018508483A5 (pt) | ||
| BR112017026189A2 (pt) | tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 | |
| RU2018129878A (ru) | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
| JP2016519650A5 (pt) | ||
| JP2018515532A5 (pt) | ||
| AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| RU2018106456A (ru) | Антитело к epha4 | |
| WO2019028182A3 (en) | TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40) | |
| JP2017527544A5 (pt) | ||
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use | |
| MX2022016039A (es) | Anticuerpos anti-cd2. | |
| RU2014117952A (ru) | Антитела против sema4a человека, используемые для лечения заболевания | |
| Espinoza et al. | Efficacy of tocilizumab in the treatment of eosinophilic fasciitis: report of one case | |
| RU2018146778A (ru) | Режим дозирования антитела к c5 | |
| MX2021005686A (es) | Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer. | |
| Lavasani et al. | Monoclonal Antibody against T‐Cell Receptor αβ Induces Self‐Tolerance in Chronic Experimental Autoimmune Encephalomyelitis | |
| AR123671A1 (es) | Anticuerpo fn14 anti-humano | |
| RU2017112967A (ru) | Лечение и функциональное излучение вич-инфекции моноклональными антителами к cd4, опосредующими конкуретное ингибирование входа вич |